This phase 1 study is to determine the optimal dose and tolerability of a hypoxia-activating agent, tirapazamine, when it is combined with embolization in live…

Hepatocellular CarcinomaGastrointestinal Cancer MetastaticNeuroendocrine Tumors

~Estimated

~$10 – $8,750

Teclison Ltd.NCT02174549

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical tria…

Cancer, MetastaticCancerCancer of Pancreas+40 more

~Estimated

~$10 – $1,050

Massive Bio, Inc.

← PreviousPage 4 of 4Next →

NCT03452774